Status:
COMPLETED
Faslodex 500mg Multiple Dose Tolerability Study in BC Patients
Lead Sponsor:
AstraZeneca
Conditions:
Advanced Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE1
Brief Summary
The primary objective of this study is to assess the tolerability of 500mg fulvestrant in postmenopausal women with hormone receptor positive, advanced or recurrent breast cancer
Eligibility Criteria
Inclusion
- Provision of written informed consent
- Postmenopausal woman who fulfils any one of the following criteria:
- Histological or cytological confirmation of breast cancer
- Estrogen receptor positive (ER+) or progesterone receptor positive (PgR+).
Exclusion
- Having received any one of the following therapy for advanced or recurrent breast cancer
- 2 or more regimens of hormonal therapy or immunotherapy or 2 or more regimens of chemotherapy, etc
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00328120
Start Date
April 1 2004
End Date
June 1 2010
Last Update
November 17 2010
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Chiba, Japan
2
Research Site
Fukuoka, Japan
3
Research Site
Nagoyata, Japan
4
Research Site
Osaka, Japan